Deriving input parameters for cost-effectiveness modeling: Taxonomy of data types and approaches to their statistical synthesis

Value in Health

Volumn 15, Issue 5, 2012, Pages 639-649

  Saramago, Pedro ^a   Manca, Andrea ^a   Sutton, Alex J ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

aggregate data; decision analytic models; economic evaluation; evidence synthesis; individual patient data; meta analysis

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TAXONOMY;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; HUMANS; MODELS, ECONOMIC; MODELS, STATISTICAL;

EID: 84864583779     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.02.009     Document Type: Article

References (133)

1. M.J. Sculpher, K. Claxton, M. Drummond, C. McCabe Whither trial-based economic evaluation for health care decision making? Health Econ 15 2006 677 687
2. M. Sculpher, K. Claxton Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient evidence? Value Health 8 2005 433 446
3. N.J. Cooper, A.J. Sutton, A.E. Ades Use of evidence in economic decision models: practical issues and methodological challenges Health Econ 16 2007 1277 1286
4. National Institute for HealthClinical Excellence Guide to the Methods of Technological Appraisal 2008 National Institute for Health and Clinical Excellence, Institute's Decision Support Unit London
5. A.E. Ades, M. Sculpher, A. Sutton Bayesian methods for evidence synthesis in cost-effectiveness analysis Pharmacoeconomics 24 2006 1 19
6. B. Mihaylova, A. Briggs, J. Armitage Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals Lancet 365 2005 1779 1785
7. B. Mihaylova, A. Briggs, J. Armitage Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people BMJ 333 2006 1145
8. A. Briggs, B. Mihaylova, M. Sculpher Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study Heart 93 2007 1081 1086
9. D.M. Epstein, M.J. Sculpher, A. Manca Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm Br J Surg 95 2008 183 190
10. M. Henriksson, D.M. Epstein, S.J. Palmer The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial Heart 94 2008 717 723
11. J.P. Higgins, A. Whitehead, R.M. Turner Meta-analysis of continuous outcome data from individual patients Stat Med 20 2001 2219 2241
12. R.D. Riley, M.C. Simmonds, M.P. Look Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods J Clin Epidemiol 60 2007 431 439
13. R.D. Riley, S.R. Dodd, J.V. Craig Meta-analysis of diagnostic test studies using individual patient data and aggregate data Stat Med 27 2008 6111 6136
14. R.D. Riley, P.C. Lambert, J.A. Staessen Meta-analysis of continuous outcomes combining individual patient data and aggregate data Stat Med 27 2008 1870 1893
15. R.D. Riley, E.W. Steyerberg Meta-analysis of a binary outcome using individual participant data and aggregate data Res Synthesis Meth 1 2010 2 19
16. A.J. Sutton, D. Kendrick, C.A. Coupland Meta-analysis of individual- and aggregate-level data Stat Med 27 2008 651 669
17. M.C. Weinstein, B. O'Brien, J. Hornberger Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies Value Health 6 2003 9 17
18. J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions 2009, v5.0.2 www.cochrane-handbook.org Accessed February 11, 2011
19. W.F. McGhan, M. Al, J.A. Doshi The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force report Value Health 12 2009 1086 1099 10.1111/j.1524-4733.2009.00605.x
20. P.C. Lambert, A.J. Sutton, K.R. Abrams, D.R. Jones A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis J Clin Epidemiol 55 2002 86 94
21. R.A. Fisher On the mathematical foundations of theoretical statistics Philos Trans Royal Soc Lond Series A 1922 309 368
22. A.E. Ades, G. Lu Correlations between parameters in risk models: estimation and propagation of uncertainty by Markov Chain Monte Carlo Risk Anal 23 2003 1165 1172
23. A.E. Ades, K. Claxton, M. Sculpher Evidence synthesis, parameter correlation and probabilistic sensitivity analysis Health Econ 15 2006 373 381
24. D. Epstein, A. Sutton Modelling correlated clinical outcomes in health technology appraisal Value Health 14 2011 793 799
25. N.J. Cooper, A.J. Sutton, K.R. Abrams Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach Health Econ 13 2004 203 226
26. L.A. Stewart, M.J. Clarke Cochrane Working Group Practical methodology of meta-analyses (overviews) using updated individual patient data Stat Med 14 1995 2057 2079
27. M. Bland An Introduction to Medical Statistics 3rd ed. 2000 Oxford University Press Oxford
28. H. Glick Economic Evaluation in Clinical Trials 2007 Oxford University Press Oxford
29. D. Collett Modelling Survival Data in Medical Research 2nd ed. 2003 Chapman & Hall/CRC Boca Raton, FL
30. A. Whitehead Meta-Analysis of Controlled Clinical Trials 2002 John Wiley & Sons Chichester
31. A.J. Sutton, J.P. Higgins Recent developments in meta-analysis Stat Med 27 2008 625 650
32. A.J. Sutton, F. Song, S.M. Gilbody, K.R. Abrams Modelling publication bias in meta-analysis: a review Stat Meth Med Res 9 2000 421 445
33. S.G. Thompson, J.P.T. Higgins How should meta-regression analyses be undertaken and interpreted? Stat Med 21 2002 1559 1573
34. S. Piantadosi, D.P. Byar, S.B. Green The ecological fallacy Am J Epidemiol 127 1988 893 904
35. J.A. Berlin, J. Santanna, C.H. Schmid Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head Stat Med 21 2002 371 387
36. J. Wakefield Ecologic studies revisited Ann Rev Pub Health 29 2008 75 90
37. A.E. Ades, G. Lu, J.P. Higgins The interpretation of random-effects meta-analysis in decision models Med Decis Making 25 2005 646 654
38. M.R. Gold Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
39. D. Turner, A. Wailoo, K. Nicholson Systematic review and economic decision modelling for the prevention and treatment of influenza A and B Health Technol Assess 7 2003 iii-iv, xi-xiii, 1-170
40. C. McKenna, J. Burch, S. Suekarran A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure Health Technol Assess 14 2010 1 162
41. S.G. Baker A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint Biostatistics 7 2006 58 70
42. V. Hasselblad, D.C. McCrory Meta-analytic tools for medical decision making: a practical guide Med Decis Making 15 1995 81 96
43. J.B. Reitsma, A.S. Glas, A.W. Rutjes Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews J Clin Epidemiol 58 2005 982 990
44. T. Lumley Network meta-analysis for indirect treatment comparisons Stat Med 21 2002 2313 2324
45. G. Lu, A.E. Ades Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 2004 3105 3124
46. A.E. Ades A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence Stat Med 22 2003 2995 3016
47. J.P. Higgins, A. Whitehead Borrowing strength from external trials in a meta-analysis Stat Med 15 1996 2733 2749
48. A. Sutton, A.E. Ades, N. Cooper, K. Abrams Use of indirect and mixed treatment comparisons for technology assessment Pharmacoeconomics 26 2008 753 767
49. S. Dias, N.J. Welton, A.E. Ades Study designs to detect sponsorship and other biases in systematic reviews J Clin Epidemiol 63 2010 587 588
50. S. Dias, N.J. Welton, D.M. Caldwell, A.E. Ades Checking consistency in mixed treatment comparison meta-analysis Stat Med 29 2010 932 944
51. G.B. Lu, A.E. Ades Assessing evidence inconsistency in mixed treatment comparisons J Am Stat Assoc 101 2006 447 459
52. G. Salanti, J.P.T. Higgins, A.E. Ades, J.P.A. Ioannidis Evaluation of networks of randomized trials Stat Meth Med Res 17 2008 279 301
53. N.J. Cooper, A.J. Sutton, D. Morris Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation Stat Med 28 2009 1861 1881
54. G. Salanti, V. Marinho, J.P. Higgins A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered J Clin Epidemiol 62 2009 857 864
55. G. Salanti, S. Dias, N.J. Welton Evaluating novel agent effects in multiple-treatments meta-regression Stat Med 29 2010 2369 2383
56. G. Lu, A.E. Ades, A.J. Sutton Meta-analysis of mixed treatment comparisons at multiple follow-up times Stat Med 26 2007 3681 3699
57. N.J. Welton, N.J. Cooper, A.E. Ades Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B Stat Med 27 2008 5620 5639
58. N. Woolacott, N. Hawkins, A. Mason Etanercept and efalizumab for the treatment of psoriasis: a systematic review Health Technol Assess 10 2006 1 233
59. A.J. Sutton, K.R. Abrams, D.R. Jones Methods for Meta-Analysis in Medical Research 2000 Wiley London
60. L.A. Stewart, J.F. Tierney To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data Eval Health Prof 25 2002 76 97
61. M.C. Simmonds, J.P. Higgins, L.A. Stewart Meta-analysis of individual patient data from randomized trials: a review of methods used in practice Clin Trials 2 2005 209 217
62. L.A. Stewart, M.K. Parmar Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 341 1993 418 422
63. G.T. Jeng, J.R. Scott, L.F. Burmeister A comparison of meta-analytic results using literature vs individual patient data: paternal cell immunization for recurrent miscarriage JAMA 274 1995 830 836
64. C.T. Smith, P.R. Williamson, A.G. Marson An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes J Eval Clin Pract 11 2005 468 478
65. R.M. Turner, R.Z. Omar, M. Yang A multilevel model framework for meta-analysis of clinical trials with binary outcomes Stat Med 19 2000 3417 3432
66. A. Whitehead, R.Z. Omar, J.P. Higgins Meta-analysis of ordinal outcomes using individual patient data Stat Med 20 2001 2243 2260
67. H. Goldstein, M. Yang, R. Omar Meta-analysis using multilevel models with an application to the study of class size effects J Roy Stat Soc C-App 49 2000 399 412
68. M.R. Farlow, G.W. Small, P. Quarg, A. Krause Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis Dement Geriatr Cogn Disord 20 2005 192 197
69. A.P. Jones, R.D. Riley, P.R. Williamson, A. Whitehead Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials Clin Trials 6 2009 16 27
70. N. Hawkins, D.A. Scott Cost-effectiveness analysis: discount the placebo at your peril Med Decis Making 30 2010 536 543
71. R.M. Nixon, N. Bansback, A. Brennan Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis Stat Med 26 2007 1237 1254
72. A. Brennan, N. Bansback, R. Nixon Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology (Oxford) 46 2007 1345 1354
73. A.J. Wailoo, N. Bansback, A. Brennan Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis Arthritis Rheum 58 2008 939 946
74. C. Jackson, N. Best, S. Richardson Improving ecological inference using individual-level data Stat Med 25 2005 2136 2159
75. C. Jackson, N. Best, S. Richardson Hierarchical related regression for combining aggregate and individual data in studies of socio-economic disease risk factors J Roy Stat Soc A 171 2008 159 178
76. A.H. Briggs, K. Claxton, M.J. Sculpher Decision Modelling for Health Economic Evaluation 2006 Oxford University Press Oxford
77. M.F. Drummond, M.J. Sculpher, G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes 3rd ed. 2005 Oxford University Press Oxford
78. H. Urdahl, A. Manca, M.J. Sculpher Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis Pharmacoeconomics 24 2006 1181 1197
79. T.C. Prevost, K.R. Abrams, D.R. Jones Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening Stat Med 19 2000 3359 3376
80. D.J. Spiegelhalter, N.G. Best Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling Stat Med 22 2003 3687 3709
81. A.E. Ades, A.J. Sutton Multiparameter evidence synthesis in epidemiology and medical decision-making: current approaches J Roy Stat Soc A 169 2006 5 35
82. A. Manca, A.R. Willan 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data Pharmacoeconomics 24 2006 1101 1119
83. K. Schulman, J. Burke, M. Drummond Resource costing for multinational neurologic clinical trials: methods and results Health Econ 7 1998 629 638
84. F. Augustovski, C. Iglesias, A. Manca Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region Pharmacoeconomics 27 2009 919 929
85. N. Cooper, D. Coyle, K. Abrams Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997 J Health Serv Res Policy 10 2005 245 250
86. S. Dias, N.J. Welton, A.J. Sutton, A.E. Ades NICE DSU Technical Support Document 5: evidence synthesis in the baseline natural history model http://www.nicedsu.org.uk/TSD%205%20Baseline-final%20report.pdf August 2011 Accessed December 19, 2011
87. D.J. Isaman, W.H. Herman, M.B. Brown A discrete-state discrete-time model using indirect observation Stat Med 25 2006 1035 1049
88. D.J.M. Isaman, J. Barhak, W. Ye Indirect estimation of a discrete-state discrete-time model using secondary data analysis of regression data Stat Med 28 2009 2095 2115
89. W. Ye, D.J.M. Isaman, J. Barhak Use of secondary data to estimate instantaneous model parameters of diabetic heart disease: lemonade method Inform Fus 13 2 2012 137 145
90. N.J. Welton, A.E. Ades Estimation of Markov chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration Med Decis Making 25 2005 633 645
91. T.K. Chao, T.H. Chen Predictive model for progression of hearing loss: meta-analysis of multi-state outcome J Eval Clin Pract 15 2009 32 40
92. G. Marshall, R.H. Jones Multi-state models and diabetic retinopathy Stat Med 14 1995 1975 1983
93. R. Cookson, C. Flood, B. Koo Short-term cost effectiveness and long-term cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal reflux disease Br J Surg 92 2005 700 706
94. J.W. Tumeh, S.G. Moore, R. Shapiro, C.R. Flowers Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis Expert Rev Pharmacoecon Outcomes Res 5 2005 153 162
95. M. Connock, E. Frew, B.W. Evans The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy: a systematic review Health Technol Assess 10 2006 iii, ix-118
96. O. Wu, L. Robertson, S. Twaddle The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis Health Technol Assess 10 2006 1 110
97. P. Bower, S. Byford, J. Barber, J. Beecham, S. Simpson, K. Friedli Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses BMJ 326 2003 1247 1250
98. R. Brooks EuroQol: the current state of play Health Policy 37 1996 53 72
99. D. Feeny, L. Wu, K. Eng Comparing short form 6D, standard gamble, and Health Utilities Index Mark 2 and Mark 3 utility scores: results from total hip arthroplasty patients Qual Life Res 13 2004 1659 1670
100. R.M. Kaplan, T.G. Ganiats, W.J. Sieber, J.P. Anderson The Quality of Well-Being Scale: critical similarities and differences with SF-36 Int J Qual Health Care 10 1998 509 520
101. J. Brazier, J. Roberts, M. Deverill The estimation of a preference-based measure of health from the SF-36 J Health Econ 21 2002 271 292
102. B. Conner-Spady, M.E. Suarez-Almazor Variation in the estimation of quality-adjusted life-years by different preference-based instruments Med Care 41 2003 791 801
103. H.L. Wee, D. Machin, W.C. Loke Assessing differences in utility scores: a comparison of four widely used preference-based instruments Value Health 10 2007 256 265
104. A. Gandjour Theoretical foundation of patient v. population preferences in calculating QALYs Med Decis Making 30 2010 E57 E63
105. T.O. Tengs, A. Wallace One thousand health-related quality-of-life estimates Med Care 38 2000 583 637
106. P.W. Sullivan, V. Ghushchyan Preference-Based EQ-5D index scores for chronic conditions in the United States Med Decis Making 26 2006 410 420
107. P.W. Sullivan, M.J. Sculpher, V.H. Ghushchyan, J.F. Slejko Catalogue of EQ-5D scores for the UK Value Health 12 2009 A398 10.1016/S1098-3015(10)74963-9 -A398.
108. D. Papaioannou, J.E. Brazier, S. Paisley NICE DSU Technical Support Document 9: the identification, review and synthesis of health state utility values from the literature http://www.nicedsu.org.uk/TSD9%20HSUV%20values-FINAL. pdf October 2011 Accessed December 19, 2011
109. M.R. Kinney, S.N. Burfitt, E. Stullenbarger Quality of life in cardiac patient research: a meta-analysis Nurs Res 45 1996 173 180
110. T.O. Tengs, T.H. Lin A meta-analysis of utility estimates for HIV/AIDS Med Decis Making 22 2002 475 481
111. T.O. Tengs, T.H. Lin A meta-analysis of quality-of-life estimates for stroke Pharmacoeconomics 21 2003 191 200
112. J. Sturza A review and meta-analysis of utility values for lung cancer Med Decis Making 30 2010 685 693
113. P.T. Donnan, D. McLernon, J.F. Dillon Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE) Health Technol Assess 13 2009 ii-iv, ix-xi, 1-134
114. A.K. Cheng, J.K. Niparko Cost-utility of the cochlear implant in adults: a meta-analysis Arch Otolaryngol Head Neck Surg 125 1999 1214 1218
115. M. Dijkers Quality of life after spinal cord injury: a meta analysis of the effects of disablement components Spinal Cord 35 1997 829 840
116. P.N. Post, A.M. Stiggelbout, P.P. Wakker The utility of health states after stroke: a systematic review of the literature Stroke 32 2001 1425 1429
117. K.E. Bremner, C.A. Chong, G. Tomlinson A review and meta-analysis of prostate cancer utilities Med Decis Making 27 2007 288 298
118. D.J. McLernon, J. Dillon, P.T. Donnan Health-state utilities in liver disease: a systematic review Med Decis Making 28 2008 582 592
119. T. Peasgood, K. Herrmann, J.A. Kanis, J.E. Brazier An updated systematic review of health state utility values for osteoporosis related conditions Osteoporos Int 20 2009 853 868
120. T. Peasgood, S. Ward, J. Brazier Health-state utility values in breast cancer Expert Rev Pharmacoecon Outcomes Res 10 2010 553 566
121. R. Ara, J.E. Brazier Populating an economic model with health state utility values: moving toward better practice Value Health 13 2010 509 518
122. R.M. Turner, D.J. Spiegelhalter, G.C. Smith, S.G. Thompson Bias modelling in evidence synthesis J R Stat Soc Ser A Stat Soc 172 2009 21 47
123. N.J. Welton, A.E. Ades, J.B. Carlin Models for potentially biased evidence in meta-analysis using empirically based priors J Roy Stat Soc A 172 2009 119 136
124. K. Abrams, C. Gillies, P. Lambert Meta-analysis of heterogeneously reported trials assessing change from baseline Stat Med 24 2005 3823 3844
125. N. Wiebe, B. Vandermeer, R. Platt A systematic review identifies a lack of standardization in methods for handling missing variance data J Clin Epidemiol 59 2006 342 353
126. T. Furukawa, C. Barbui, A. Cipriani Imputing missing standard deviations in meta-analyses can provide accurate results J Clin Epidemiol 59 2006 7 10
127. J. Nixon, K. Khan, J. Kleijnen Summarising economic evaluations in systematic reviews: a new approach Brit Med J 322 2001 1596 1598
128. S. Birch, A. Gafni Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results Health Policy 64 2003 207 219
129. M.J. Sculpher, F.S. Pang, A. Manca Generalisability in economic evaluation studies in healthcare: a review and case studies Health Technol Assess 8 2004 iii-iv,1-192
130. R. Welte, T. Feenstra, H. Jager, R. Leidl A decision chart for assessing and improving the transferability of economic evaluation results between countries Pharmacoeconomics 22 2004 857 876
131. M. Pignone, S. Saha, T. Hoerger Challenges in systematic reviews of economic analyses Ann Intern Med 142 2005 1073 1079
132. M.J. Sculpher, M.F. Drummond Analysis sans frontieres: can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics 24 2006 1087 1099
133. R. Anderson Systematic reviews of economic evaluations: utility or futility? Health Econ 19 2010 350 364